Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Lupin Partners with Sandoz to Commercialise Ranibizumab Biosimilar in EU & APAC

Aug 12, 2025

On 12 August 2025, Lupin announced that it has partnered with Sandoz to market and commercialise Lupin’s biosimilar ranibizumab (referencing Genentech’s Lucentis®) across the European Union (excluding Germany), Switzerland, Norway, Canada, Australia, Hong Kong, Vietnam, and Malaysia.  

Sandoz has exclusive marketing rights in most of the designated markets, except for France, Australia, Vietnam, and Malaysia, where it has semi-exclusive marketing rights.  Lupin remains responsible for manufacturing the product and for regulatory submissions.

Lupin is one a of a number of companies with ranibizumab biosimilars.  Other ranibizumab biosimilars include Samsung Bioepis’ Byooviz® (EU-approved in September 2021, FDA-approved in September 2021); Formycon’s Ranivisio® (EU-approved in August 2022); Sandoz’s Cimerli® (FDA-approved in August 2022) and STADA/Xbrane’s Ximluci® (EU-approved 9 November 2022).